| Old Articles: <Older 7441-7450 Newer> |
|---|
 |
The Motley Fool
May 12, 2011
Arundhati Parmar |
Analysts: Medtronic CEO Omar Ishrak Good Choice Ishrak represents a change at Medtronic.   |
Pharmaceutical Executive
May 1, 2011
Mason Tenaglia |
Out of Control The pharmaceutical industry needs to use new and better data to accurately measure how much it is willing to invest in avoiding plan control. |
Pharmaceutical Executive
May 1, 2011
Cacciotti & Clinton |
12th Annual Pharm Exec 50 Pharm Exec's annual run-down of the world's biggest pharma companies. |
Pharmaceutical Executive
May 1, 2011 |
The Cloud and Beyond Cloud computing is becoming the IT platform of choice for pharma, affecting nearly every aspect of business. |
Pharmaceutical Executive
May 1, 2011
John F. Brenner |
Expanded Liability for Generic, Brand Manufacturers Ahead? To what extent are generics companies obligated by law to request labeling changes with FDA? |
Pharmaceutical Executive
May 1, 2011
Jill Wechsler |
Outrage Over Drug Prices Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies |
Pharmaceutical Executive
May 1, 2011
Amit Rakhit |
Using Social Networks to Guide Product Spend Online sentiment analysis monitoring can help biopharma resource managers make crucial decisions. |
Pharmaceutical Executive
May 1, 2011
Stan Bernard |
Competition 2.0: Brands vs. Generics Innovator and generics companies are colliding as they invade each other's turf. |
Pharmaceutical Executive
May 1, 2011
Thompson & Twait |
High-Risks to High Reward According to Eli Lilly, managing alliances requires more than good people skills. |
Pharmaceutical Executive
May 1, 2011
Julian Upton |
UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance. |
| <Older 7441-7450 Newer> Return to current articles. |
